nVerses Capital’s GoodRx Holdings GDRX Stock Holding History

nVerses Capital’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,800	Closed	-$33.3K	–	334
2024 Q3	$33.3K	Buy	+4,800	New	+$37.7K	0.02%	726

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

LCM

Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RRCP

Rip Road Capital Partners Boston, Massachusetts $62.5M AUM 1.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

nVerses Capital's GDRX Position: Q4 2024 in Review

nVerses Capital sold out of GoodRx Holdings (GDRX) in Q4 2024, closing a stake of 4,800 shares — an estimated $33.3K sold.

nVerses Capital first reported a position in GDRX in Q3 2024 and held it in 1 quarter. The position peaked at $33.3K in Q3 2024. 170 funds tracked by Wall St. Rank hold GDRX as of Q4 2024.

nVerses Capital reported no remaining GoodRx Holdings position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 4,800 GoodRx Holdings shares in Q4 2024, an estimated $33.3K.
nVerses Capital first reported a position in GoodRx Holdings in Q3 2024 and held it in 1 quarter.
nVerses Capital's GoodRx Holdings position peaked at $33.3K in Q3 2024.
170 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.